Cargando…
Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
Combination treatment has proven effective for patients with acute promyelocytic leukemia, exemplifying the importance of therapy targeting multiple components of oncogenic regulation for a successful outcome. However, recent studies have shown that the mutational complexity of acute myeloid leukemi...
Autores principales: | Hultmark, Simon, Baudet, Aurélie, Schmiderer, Ludwig, Prabhala, Pavan, Palma-Tortosa, Sara, Sandén, Carl, Fioretos, Thoas, Sasidharan, Rajkumar, Larsson, Christer, Lehmann, Sören, Juliusson, Gunnar, Ek, Fredrik, Magnusson, Mattias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485661/ https://www.ncbi.nlm.nih.gov/pubmed/32855276 http://dx.doi.org/10.3324/haematol.2020.249177 |
Ejemplares similares
-
Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations
por: Subramaniam, Agatheeswaran, et al.
Publicado: (2022) -
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017) -
The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
por: Wong, C, et al.
Publicado: (2014) -
Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism
por: Kumstel, Simone, et al.
Publicado: (2022) -
IL1RAP is expressed in several subtypes of pediatric acute lymphoblastic leukemia and can be used as a target to eliminate ETV6::RUNX1-positive leukemia cells in preclinical models
por: Ågerstam, Helena, et al.
Publicado: (2022)